A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — At 3 years, the Amplatzer Amulet device ...

GENT, Belgium--(BUSINESS WIRE)--FEops today announced that it received authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial ...

Left atrial appendage occlusion (LAAO) is associated with fewer injuries and less bleeding from falls than anticoagulant medications in patients with atrial fibrillation (AF) and a previous stroke, a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a letter to health care providers in response to a recent study that evaluated differences in ...

NEW ORLEANS – Standard medical care seemed to be a better bet than a catheter-based procedure in high-risk patients with atrial fibrillation (Afib), according to the CLOSURE-AF study. The trial had a ...

NASHUA, N.H., Oct. 14, 2025 /PRNewswire/ -- Conformal Medical, Inc., a medical device company developing next-generation technology for left atrial appendage occlusion (LAAO), today announced the ...

The odds of complications and early mortality are higher among LAAO recipients with kidney impairment. Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) increase the risks for ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is increasing in incidence and ...

Women have more in-hospital complications than men and double the risk for major adverse events after left atrial appendage occlusion (LAAO) with the Watchman device, according to new National ...